XV Eurasian Hematology-Oncology Congress - EHOC 2024

 

Leukemia
22:08

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Pediatric ALL: Etiology, Diagnosis and Management

FEATURING ÖZlem TüFekçI GüRocak
  • 23 views
  • October 15, 2024
23:50

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

FEATURING Mohamed Isam Sharif
  • 9 views
  • October 15, 2024
15:42

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CLL Case: Acquired Del(17p) at Relapse

FEATURING Melis Dila Özer Çerme
  • 8 views
  • October 15, 2024
03:40

XV Eurasian Hematology-Oncology Congress - EHOC 2024

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

FEATURING Kubra Ozsoy
  • 3 views
  • October 15, 2024
15:34

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Novel Agents in the Treatment of R/R CLL

FEATURING Nitin Jain
  • 44 views
  • October 9, 2024
17:52

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Venetoclax-Based Regimens in AML: Understanding Resistance and Developing Novel Combinations

FEATURING Naval Daver
  • 119 views
  • October 8, 2024
16:58

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

FEATURING Naval Daver
  • 38 views
  • October 8, 2024
22:58

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL Treatment: Distinct Entity or Continuous Process

FEATURING Nevenka Ridova
  • 9 views
  • October 6, 2024
12:18

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in CLL: Continuous or Finite Duration Therapy

FEATURING Nitin Jain
  • 165 views
  • October 6, 2024
17:45

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Ph+ ALL Management: Case-Based Discussion

FEATURING Kivanc Koruk
  • 20 views
  • September 27, 2024
17:37

XV Eurasian Hematology-Oncology Congress - EHOC 2024

AML Case Discussion: FLT3-ITD+ High-Risk Disease

FEATURING Fehmi Hindilerden
  • 25 views
  • September 27, 2024
18:32

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With R/R ALL

FEATURING Elias Jabbour
  • 42 views
  • September 27, 2024
  • 1
15:51

XV Eurasian Hematology-Oncology Congress - EHOC 2024

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

FEATURING Elias Jabbour
  • 26 views
  • September 27, 2024
20:29

XV Eurasian Hematology-Oncology Congress - EHOC 2024

TKI Discontinuation in CML: Defining Eligibility Criteria and Predictors of Success

FEATURING Mohamed A. Yassin
  • 29 views
  • September 25, 2024
07:49

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A Case of CMML With Recurrent Skin Involvement

FEATURING Eren Arslan Davulcu
  • 13 views
  • September 16, 2024
15:14

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Critical Re-Evaluation of Established Practices in CML Management

FEATURING Hagop Kantarjian
  • 173 views
  • September 16, 2024
  • 1
28:43

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Management of R/R AML: Treatment Options and Case Insights

FEATURING Valentina Bonuomo
  • 42 views
  • September 11, 2024
19:01

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 7+3 Is No Longer the Standard of Care

FEATURING Tapan Kadia
  • 726 views
  • September 11, 2024
  • 9
14:17

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Practical Approach to MRD Monitoring in AML: Assessing Treatment Efficacy and Relapse Risk

FEATURING Tapan Kadia
  • 108 views
  • September 11, 2024
10:30

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

FEATURING Dieter Hoelzer
  • 31 views
  • September 6, 2024
09:06

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patients

FEATURING Elias Jabbour
  • 43 views
  • September 6, 2024
23:52

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CLL Case Discussion: First Line Treatment Strategies

FEATURING Damla Ortaboz
  • 60 views
  • September 6, 2024
18:01

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Incorporation of Targeted and Immunotherapies in ALL

FEATURING Hagop Kantarjian
  • 230 views
  • August 30, 2024
  • 1
18:49

XV Eurasian Hematology-Oncology Congress - EHOC 2024

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxicity Management

FEATURING Ebru Erdogan
  • 15 views
  • August 30, 2024
17:13

XV Eurasian Hematology-Oncology Congress - EHOC 2024

The Importance of MRD in ALL

FEATURING Farhad Ravandi
  • 183 views
  • August 29, 2024
22:26

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Management of AML in Older Patients

FEATURING Farhad Ravandi
  • 204 views
  • August 29, 2024
34:29

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Current Approaches to Managing T-Cell ALL

FEATURING Ahmad Ibrahim
  • 23 views
  • August 28, 2024
15:10

XV Eurasian Hematology-Oncology Congress - EHOC 2024

TKI Toxicity Management in CML: A Case-Based Discussion

FEATURING Awni Alshurafa
  • 20 views
  • August 15, 2024
18:56

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Management of Persistently MRD+ ALL

FEATURING Asli Odabasi Giden
  • 36 views
  • August 15, 2024
18:07

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Debates in AML: 3+7 is the SOC Induction Therapy for AML

FEATURING Ant Uzay
  • 58 views
  • August 15, 2024
  • 1
11:33

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs

FEATURING Ahmet Sarici
  • 31 views
  • August 15, 2024
16:19

XV Eurasian Hematology-Oncology Congress - EHOC 2024

Current Options for Finite-Duration Therapy With BTKis in CLL

FEATURING Ahmad Ibrahim
  • 149 views
  • August 13, 2024